As B7-H3 promoted tumor angiogenesis in CRC via the NF-κB/VEGFA signaling pathway, we wondered whether B7-H3 blockade and BAY11–7082 or bevacizumab co-treatment exerts synergetic effects on the inhibition of angiogenesis in vivo. Here, VEGFA is linked to neoplasm.